All stock lists
Optimi Health Corp. (NASDAQ:OPTH)
CA · Delayed Price · Currency is USD
Also listed: OPTI.CNHealthcare · Drug Manufacturers - Specialty & Generic
$2.26+$0.08 (+3.67%)
Insider Score
––Not scored
OPTH Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Weak
From OPTH’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $134K
- Net income
- -$6.2M
- Net margin
- -4611.0%
Leverage17 / 20
Little or no net debt.
- Total debt
- $3.6M
- Cash
- $9.2M
- Debt / equity
- 0.29
Liquidity16 / 20
Comfortably covers what is due within a year.
- Current assets
- $9.8M
- Current liabilities
- $5.7M
- Current ratio
- 1.73
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$4.4M
- Free cash flow
- -$4.5M
- FCF margin
- -3323.1%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 4.3M
- Share growth (1y)
- 33.4%
- Cash runway
- 25 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
OPTH Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $98.70 K | $99.50 K | $0.00 | -$64.03 K | $196.39 K | $61.24 K |
| Revenue Growth (YoY) | -49.74 % | 62.47 % | -100.00 % | -210.66 % | 58.34 % | -26.12 % |
| Cost of Revenue | $397.40 K | $10.04 K | $264.53 K | $400.20 K | $14.46 K | $17.30 K |
| Gross Profit | -$298.70 K | $89.46 K | -$264.53 K | -$464.23 K | $181.93 K | $43.94 K |
| SG&A Expense | $675.67 K | $778.00 K | $665.13 K | $776.96 K | $515.12 K | $676.60 K |
| R&D Expense | $82.72 K | $38.80 K | $48.45 K | $144.20 K | $1.50 K | $42.24 K |
| Operating Expenses | $1.20 M | $1.45 M | $1.02 M | $1.20 M | $979.71 K | $1.03 M |
| Operating Income | -$1.50 M | -$1.36 M | -$1.28 M | -$1.67 M | -$797.78 K | -$989.05 K |
| Pretax Income | -$1.69 M | -$1.59 M | -$1.55 M | -$1.35 M | -$907.32 K | -$196.37 K |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.69 M | -$1.59 M | -$1.55 M | -$1.35 M | -$907.32 K | -$196.37 K |
| EPS (Basic) | -$0.39 | -$0.49 | -$0.48 | -$0.42 | -$0.28 | -$0.06 |
| EPS (Diluted) | -$0.39 | -$0.49 | -$0.48 | -$0.42 | -$0.28 | -$0.06 |
| Shares Outstanding | 4.30 M | 3.22 M | 3.22 M | 3.20 M | 3.22 M | 3.20 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.